CC
ADAP

Courier Capital’s Adaptimmune Therapeutics ADAP Stock Holding History

Courier Capital’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,000
Closed -$9.36K – 356
2023
Q3 		$9.36K Buy
+12,000
New +$10.1K ﹤0.01% 340

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Courier Capital's ADAP Position: Q4 2023 in Review

Courier Capital sold out of Adaptimmune Therapeutics (ADAP) in Q4 2023, closing a stake of 12,000 shares — an estimated $9.36K sold.

Courier Capital first reported a position in ADAP in Q3 2023 and held it in 1 quarter. The position peaked at $9.36K in Q3 2023. 79 funds tracked by Wall St. Rank hold ADAP as of Q4 2023.

  • Courier Capital reported no remaining Adaptimmune Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Courier Capital sold 12,000 Adaptimmune Therapeutics shares in Q4 2023, an estimated $9.36K.
  • Courier Capital first reported a position in Adaptimmune Therapeutics in Q3 2023 and held it in 1 quarter.
  • Courier Capital's Adaptimmune Therapeutics position peaked at $9.36K in Q3 2023.
  • 79 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2023.

Based on Courier Capital's 13F filing for Q4 2023, filed 17 Jan 2024.